Has Aleksandra Florek, MD received payments from drug or device companies?

Yes. Drug and device makers reported $26,414 in general payments to Aleksandra Florek, MD across 870 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aleksandra Florek, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aleksandra Florek, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aleksandra Florek, MD

Dermatology · Crown Point, INNPI 1417364670

Payments from drug & device makers

$26,414in general payments, 2019–2025

Across 870 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$6K
AbbVie$5K
E.r. Squibb & Sons, L.L.C.$2K
Pfizer$2K
Regeneron Healthcare Solutions, Inc.$1K
Sun Pharmaceutical Industries Inc.$1K
plus $9K from 26 others

What the payments were for

Consulting fees$6,01323%
Food & beverage$19,57274%
Education$8303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	66	$5,930
AbbVie(2 entities)	214	$5,453
E.r. Squibb & Sons, L.L.C.	56	$2,224
Pfizer	68	$1,545
Regeneron Healthcare Solutions, Inc.	33	$1,130
Sun Pharmaceutical Industries Inc.	45	$1,067
Lilly USA, LLC	50	$1,046
Novartis	45	$1,016
Incyte Corporation	43	$960
Dermavant Sciences, Inc.	48	$870
Sanofi	25	$743
UCB, Inc.	25	$673
LEO Pharma Inc.	29	$656
Galderma Laboratories, L.p.	30	$560
Almirall LLC	15	$360
Arcutis Biotherapeutics, Inc.	16	$352
Amgen	12	$345
Organon	8	$249
Janssen Scientific Affairs, LLC	2	$226
EPI Health, LLC	9	$177
Kerecis Limited	4	$172
Merck	2	$126
Ortho Dermatologics, A Division Of Bausch Health US, LLC	5	$87
Boehringer Ingelheim	2	$70
Endo Pharmaceuticals Inc.	1	$68
Sanofi-aventis U.S. LLC	2	$58
Convatec Inc.	1	$55
Strata Skin Sciences, Inc.	6	$49
Organogenesis Inc.	3	$48
LNHC, Inc	2	$46
Biofrontera Inc.	2	$38
Smith+Nephew	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$4,857
Rinvoq$726
Skyrizi$472
VTAMA$433
DUPIXENT$375
CIBINQO$227
Sotyktu$206
ANZUPGO$141
Otezla$126
OPZELURA$125
Klisyri$123
LITFULO$121
KEYTRUDA$112
Bimzelx$111
ZORYVE$106

How this compares

$26,414 in reported general payments places this provider in the 85th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana →

Medicare billing

Part B allowed, 2024

$1,014,191

Medicare patients

1,069

Services billed

6,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	24	$500,716
Cosentyx Unoready PenSecukinumab	11	$104,252
Taltz AutoinjectorIxekizumab	13	$93,666
Fluorouracil	183	$13,771
Doxycycline Monohydrate	690	$11,171
Clobetasol Propionate	203	$8,805
Acitretin	12	$4,589
Triamcinolone Acetonide	254	$4,402
Mupirocin	497	$3,537
Ketoconazole	270	$3,280
Doxycycline Hyclate	165	$2,305
Betamethasone Dipropionate	27	$2,030
ValacyclovirValacyclovir Hcl	36	$1,976
Gentamicin Sulfate	34	$1,575
CiclopiroxCiclopirox Olamine	57	$1,268

Paid to pharmacies, not to this prescriber.

Other dermatology in Crown Point

Ashvin GarlapatiCrown Point$170K
Scott GuenthnerPlainfield$10.7M
Scott FretzinIndianapolis$9.8M
David RosmarinIndianapolis$4.4M
Holly Hake HarrisSouth Bend$3.4M
Megan LandisCorydon$2.8M
Kenneth DawesIndianapolis$2.2M
Ginat MirowskiIndianapolis$1.8M
Vassilios DimitropoulosMichigan City$1.8M
Christopher ObeimeIndianapolis$907K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →